Ahmed Ismail1, Farah M Shurrab2, Hadeel T Al-Jighefee2,3, Duaa W Al-Sadeq2,4, Hamda Qotba5,6, Ibrahim Abdu Al-Shaar1, Hadi M Yassine2,3, Laith J Abu-Raddad7,8,9, Gheyath K Nasrallah2,3. 1. Laboratory Section, Medical Commission Department, Ministry of Public Health, 42 Doha, Qatar. 2. Biomedical Research Center, Qatar University, 2713 Doha, Qatar. 3. Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, 2713 Doha, Qatar. 4. College of Medicine, Member of QU Health, Qatar University, 2713 Doha, Qatar. 5. Department of Clinical Research, Primary Health Care Centers, 26555 Doha, Qatar. 6. Department of Pathology, Sidra Medicine, 26999 Doha, Qatar. 7. Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, 24144 Doha, Qatar. 8. World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, 24144 Doha, Qatar. 9. Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA.
Abstract
Background: High-throughput assays that can infer neutralizing activity against SARS-CoV-2 are of great importance for assessing the immunity induced by natural infection and COVID-19 vaccines. We aimed to evaluate the performance and degree of correlation of three fully automated anti-SARS-CoV-2 immunoassays with neutralization activity using a surrogate virus-neutralizing test (sVNT) from GenScript, targeting the receptor-binding domain. Methods: 110 sera collected from PCR-confirmed asymptomatic COVID-19 individuals were tested for neutralizing antibodies (nAbs) using the sVNT. Positive samples were tested on three automated immunoassays targeting different viral antigens: Mindray CL-900i®, Abbott Architect, and Ortho VITROS®. The diagnostic sensitivity, specificity, agreement, and correlation with the sVNT were assessed. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal thresholds for predicting the presence of neutralizing activity by each assay. Results: All three assays showed 100% specificities. The highest sensitivity was 99.0%, demonstrated by VITROS®, followed by 94.3%, for CL-900i®, and 81.0%, for Architect. Both VITROS® and CL-900i® had the strongest correlation with the sVNT (ρ = 0.718 and ρ = 0.712, respectively), while Architect showed a moderate correlation (ρ = 0.618). ROC curve analysis indicated that the manufacturer's recommended cutoff values are adequate for predicting the presence of nAbs and providing a strong correlation with the sVNT. Conclusion: VITROS® and CL-900i® serological assays, which detect antibodies against SARS-CoV-2 spike protein, could serve as reliable assays to predict neutralization activity after infection or vaccination.
Background: High-throughput assays that can infer neutralizing activity against SARS-CoV-2 are of great importance for assessing the immunity induced by natural infection and COVID-19 vaccines. We aimed to evaluate the performance and degree of correlation of three fully automated anti-SARS-CoV-2 immunoassays with neutralization activity using a surrogate virus-neutralizing test (sVNT) from GenScript, targeting the receptor-binding domain. Methods: 110 sera collected from PCR-confirmed asymptomatic COVID-19 individuals were tested for neutralizing antibodies (nAbs) using the sVNT. Positive samples were tested on three automated immunoassays targeting different viral antigens: Mindray CL-900i®, Abbott Architect, and Ortho VITROS®. The diagnostic sensitivity, specificity, agreement, and correlation with the sVNT were assessed. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal thresholds for predicting the presence of neutralizing activity by each assay. Results: All three assays showed 100% specificities. The highest sensitivity was 99.0%, demonstrated by VITROS®, followed by 94.3%, for CL-900i®, and 81.0%, for Architect. Both VITROS® and CL-900i® had the strongest correlation with the sVNT (ρ = 0.718 and ρ = 0.712, respectively), while Architect showed a moderate correlation (ρ = 0.618). ROC curve analysis indicated that the manufacturer's recommended cutoff values are adequate for predicting the presence of nAbs and providing a strong correlation with the sVNT. Conclusion: VITROS® and CL-900i® serological assays, which detect antibodies against SARS-CoV-2spike protein, could serve as reliable assays to predict neutralization activity after infection or vaccination.
Authors: Duaa W Al-Sadeq; Farah M Shurrab; Ahmed Ismail; Fathima Humaira Amanullah; Swapna Thomas; Nader Aldewik; Hadi M Yassine; Hanan F Abdul Rahim; Laith Abu-Raddad; Gheyath K Nasrallah Journal: J Travel Med Date: 2021-12-29 Impact factor: 8.490
Authors: Farah M Shurrab; Duaa W Al-Sadeq; Haissam Abou-Saleh; Nader Al-Dewik; Amira E Elsharafi; Fatima M Hamaydeh; Bushra Y Abo Halawa; Tala M Jamaleddin; Huda M Abdul Hameed; Parveen B Nizamuddin; Fathima Humaira Amanullah; Hanin I Daas; Laith J Abu-Raddad; Gheyath K Nasrallah Journal: Vaccines (Basel) Date: 2022-01-25
Authors: Farah M Shurrab; Nadin Younes; Duaa W Al-Sadeq; Na Liu; Hamda Qotba; Laith J Abu-Raddad; Gheyath K Nasrallah Journal: Int J Infect Dis Date: 2022-02-26 Impact factor: 12.074
Authors: Nadin Younes; Duaa W Al-Sadeq; Farah M Shurrab; Hadeel T Zedan; Haissam Abou-Saleh; Bushra Y Abo-Halawa; Fatima M AlHamaydeh; Amira E Elsharafi; Hanin I Daas; Swapna Thomas; Sahar Aboalmaaly; Afra Al Farsi; Reeham Al-Buainain; Samar Ataelmannan; Jiji Paul; Amana Salih Al Saadi; Hadi M Yassine; Amin F Majdalawieh; Ahmed Ismail; Laith J Abu-Raddad; Gheyath K Nasrallah Journal: Vaccines (Basel) Date: 2022-08-15